Monsanto’s smear merchant, the Genetic Literacy Project, is now Bayer’s bully
By Jonathan Matthews,
GMWatch
| 08. 31. 2022
Recently the Genetic Literacy Project has been heavily targeting critics of the herbicide Roundup, now owned by Bayer, with a barrage of articles, podcasts, and tweets, in which the controversial University of Florida scientist Kevin Folta has been much to the fore.
It all started when the Guardian published a piece by the award-winning journalist Carey Gillam on a CDC study showing the prevalence in urine samples in the US of Roundup’s controversial active ingredient glyphosate, which has been linked to cancer.
Kevin Folta led the charge for the GLP with a piece that labelled the Guardian article the latest example of “yellow journalism” (i.e. lurid, sensationalist reporting), not to mention “deceptive journalism”, by “scientifically illiterate journalists”. Folta then gave over a further three paragraphs to attacking Gillam personally and outlining his version of her “ethically questionable history”. This somehow failed to mention that, among other things, she won a Society of Environmental Journalists’ book award or that her former colleagues at Reuters say she is “an exceptional journalist” who produces “impeccably reported” stories.
“Slimeball tactics”
The GLP, which has...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
